# **Transforming Spine Surgery Through Personalized Solutions**

Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.

### Technology Platform

A fully integrated, end-to-end platform for personalized spinal care.

Data-driven 3D surgical planning and visualization, precision alignment, and optimized fit.​

[Learn More](/content/aprevo-technology-platform/index.html)

### Advancing what’s possible through personalized spinal solutions

Each device is tailored to the individual patient – explore why patients want personalized care and how it makes a difference.

aprevo® Technology Reel from VoxMD on Vimeo

Playing in picture-in-picture

Play

Settings

QualityAuto

Picture-in-Picture

Fullscreen

;

aprevo® Portfolio

**Personalized surgical procedures**

[Learn more](/#)

myaprevo®

**3D visualization**

[Learn more](/#)

aprevo® Clinical Evidence

**A foundation built on data**

[Learn more](/#)

### Latest Investor News

- July 22, 2026  
  [Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-inc-report-second-quarter-2026-financial-results-august)  
  CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2026 financial results after market close on  
  [Read More →](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-inc-report-second-quarter-2026-financial-results-august)

- May 5, 2026  
  [Carlsmed® Reports First Quarter 2026 Financial Results](https://investors.carlsmed.com/news-releases/news-release-details/carlsmedr-reports-first-quarter-2026-financial-results)  
  First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company  
  [Read More →](https://investors.carlsmed.com/news-releases/news-release-details/carlsmedr-reports-first-quarter-2026-financial-results)

- April 28, 2026  
  [Carlsmed, Inc. To Participate in Upcoming Investor Conferences](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-inc-participate-upcoming-investor-conferences)  
  CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences. Bank of America Global Healthcare Conference in Las  
  [Read More →](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-inc-participate-upcoming-investor-conferences)

### Contact Us

Learn about our personalized procedural solutions.

[Contact Us](/#)

### Patient Support

Learn about your personalized procedure.

[Learn More](https://personalizedspine.com/)

### Coding & Reimbursement Support

Coding or reimbursement questions?

Contact Us

aprevo® is FDA-cleared in the U.S. for lumbar and cervical spinal fusion indications only.